Keisuke Kawamoto

4PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Nov 06, 2018
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.

Keisuke Kawamoto, Takaharu Suzuki, Takuya Kasami

|Mar 31, 2018
Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.

Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki

|Oct 21, 2017
Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.

Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki

|Jan 28, 2017
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.

Keisuke Kawamoto, Hiroaki Miyoshi, Eriko Yanagida

Pageof 1

Frequent Collaborators